XML 22 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Acquisition of Totipotent RX (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
12 Months Ended 0 Months Ended 4 Months Ended 12 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2012
Jan. 30, 2014
Feb. 18, 2014
TotipotentRX Corporation [Member]
Jun. 30, 2014
TotipotentRX Corporation [Member]
Jun. 30, 2014
TotipotentRX Corporation [Member]
Subsidiary
Jun. 30, 2013
TotipotentRX Corporation [Member]
Feb. 18, 2014
TotipotentRX Corporation [Member]
Officer
Business Acquisition [Line Items]                  
Number of wholly owned subsidiaries             2    
Recorded revenues during the year           $ 351      
Recorded net loss during the year           277      
Acquisition related costs 1,958 921         1,715    
Aggregate number of shares issued (in shares)         12,490,841        
Percentage of common stock issued to acquiree shareholders (in hundredths)                 38.00%
Fair value of aggregate number of shares issued                 27,105
Number of convertible shares in exchange of warrants issued (in shares) 2,259,000     1,668,400         61,020
Warrant issued in relation to business acquisition (in shares)                 61,020
Fair value of common stock in exchange of warrants issued                 52
Increase in clinical protocols           13,829 13,829    
Decrease in other intangible assets           527 527    
Increase in other liabilities           385 385    
Decrease in goodwill           5,639 5,639    
Purchase Price [Abstract]                  
ThermoGenesis common shares and warrants         27,287        
Fair value of assets acquired [Abstract]                  
Cash                 351
Receivables                 171
Inventories                 191
Clinical protocols                 19,870
Other intangible assets                 2,187
Property and equipment                 325
Other assets                 132
Total assets                 23,227
Fair value of liabilities assumed [Abstract]                  
Accounts payable                 514
Related party notes payable                 337
Deferred tax liability                 8,048
Other liabilities                 295
Total liabilities                 9,194
Net assets acquired                 14,033
Preliminary goodwill 13,254 0             13,254
Business Acquisition, Pro Forma Information [Abstract]                  
Net revenues             16,619 19,279  
Net income (loss)             (7,922) (4,228)  
Settlement of receivables and payables between merging companies                 130
Gross contractual amounts receivable                 232
Number of officers whom repayment of notes payable                 2
Repayment of each officer notes payable             75    
Repayment of related party notes payable $ 150 $ 0 $ 0       $ 150    
Shares issued to satisfy the remainder of debt (in shares)                 82,000